Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
mylan pharmaceuticals
28 tablet
Sofosbuvir and Velpatasvir
Keep in cold place
Delivering To:
Overview
Two antiviral medications are combined in Myhep All Tablet. Chronic hepatitis C virus (HCV) infection is treated with this prescription medication. The active ingredients of Myhep All tablets are Velpatasvir and Sofosbuvir. It helps by reducing the virus's ability to multiply within the body. Over time, a 400 mg Myhep tablet gradually improves liver function. The duration of time may vary depending on a number of factors, including liver cirrhosis, prior treatment history, and HCV genotype. Reducing the virus may significantly decrease the incidence of liver cirrhosis, liver failure, and hepatocellular carcinoma, a kind of liver cancer.
Hepatitis C
Chronic hepatitis C (HCV) infection.
MyhepAll 400 mg tablet may cause certain side effects. If side effects occur after administration or last longer than usual, contact your healthcare professional. Headache
Fatigue
Nausea
Insomnia
Diarrhea
Itching
Decreased appetite
Muscle or joint pain
Hepatitis B reactivation
Severe allergic reactions
As directed by your physician, take this medication for the prescribed duration of time. Eat it all at once. Avoid chewing, crushing, or breaking it. It is preferable to take Myhep All Tablet at a set time, however it can be taken with or without food. Don't forget to take your medication. Tell your doctor if you fail to take your medications on time.
Sofosbuvir and Velpatasvir are two antiviral medications that are combined in Myhep All Tablet. They function by gradually removing the hepatitis C virus from the blood and reducing its levels in the body. By focusing on a particular protein required for viral reproduction, the direct-acting antiviral medication (DAA) sofosbuvir prevents the HCV virus from replicating. Another DAA that functions by preventing the activity of a different protein implicated in HCV replication is velpatasvir.
Alcohol
unsafe
It is advisable not to consume alcohol while taking this medicine.
Pregnancy
consult your doctor
Do not take MyhepAll 400 mg tablet without consulting the doctor, in case of pregnancy.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
caution
Do not take Myhep 400 mg tablet without a doctor's consultation in case of kidney problems.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine.
It is suggested you that do not skip your medicines. If you forget to take your medication then contact your doctor immediately.
Myhep All Tablet medicine is a combination of Sofosbuvir and Velpatasvir, which are also called antiviral medicines.
They work by fighting against of hepatitis C virus in the body and resolving the infection.
The common side effects of this medicine are headaches and fatigue.
During your treatment follow the suggestion which is given by your expert or doctor.
Take Myhep All Tablet as soon as you remember to do so. On the other hand, skip the missed dose and restart your usual routine if your next dose is almost due. Avoid taking two doses at once.
Yes, in order to track liver function, viral load, and treatment response, routine blood tests are usually performed during Myhep All pill treatment. These tests aid in determining the medication's efficacy and guarantee patient safety.
Butt, N., Muhammad, I., Abou Bakr, A., Akhtar, Z., Ali, M., & Maheshwary, N. (2020). Efficacy and safety of Sofosbuvir-velpatasvir combination in Pakistani HCV patients without or with compensated cirrhosis. Cureus, 12(1), e6537. https://doi.org/10.7759/cureus.6537
Goel, A., Chen, Q., Chhatwal, J., & Aggarwal, R. (2018). Cost-effectiveness of generic pan‑genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment in India. Journal of Gastroenterology and Hepatology, 33(12), 2029–2036. https://doi.org/10.1111/jgh.14301
Tan, Y. M., et al. (2023). Real‑world impact of the subsidy decision of sofosbuvir‑velpatasvir for chronic hepatitis C: trends in utilization and SVR outcomes in Malaysia. JGH Open. https://doi.org/10.1002/jgh3.12850
Springer. Gaur, N., et al. (2020). Sofosbuvir‑velpatasvir fixed-dose combination for chronic hepatitis C infection in end-stage renal disease patients on maintenance hemodialysis: An Indian single-center experience. Journal of Clinical and Experimental Hepatology. Retrieved from PubMed. Shah, V., et al. (2023). Sofosbuvir/velpatasvir/voxilaprevir for retreatment of difficult-to-treat chronic HCV patients in India: Real-life observational cohort. Journal of Clinical and Experimental Hepatology. https://pubmed.ncbi.nlm.nih.gov/38261859/
Huang, C.-T., et al. (2021). Sofosbuvir/velpatasvir for chronic hepatitis C virus infection: real‑world effectiveness and safety from a nationwide registry in Taiwan. Infectious Diseases and Therapy, 10(3), 1185–1196. https://doi.org/10.1007/s40121-021-00576-7
